The challenge of selecting protein kinase assays for lead discovery optimization

Expert Opinion on Drug Discovery

Volumn 3, Issue 6, 2008, Pages 607-621

  Ma, Haiching ^a   Deacon, Sean ^a   Horiuchi, Kurumi ^a  

^a Raction Biology Corporation   (United States)

Author keywords

Drug discovery; Drug profiling; Drug screening; ELISA; Florescence resonance energy transfer; Fluorescence polarization; Kinase assay; Kinase profiling; Luminescence assays; Radioisotope filtration binding assay; Time resolved fluorescence resonance energy transfer

Indexed keywords

BMS 354285; CAPECITABINE; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; REAGENT; SORAFENIB; ST 571; SUNITINIB; TEMSIROLIMUS;

BINDING ASSAY; DRUG DESIGN; DRUG INDUSTRY; DRUG TARGETING; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE ANALYSIS; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GEL MOBILITY SHIFT ASSAY; HIGH THROUGHPUT SCREENING; INFLAMMATORY DISEASE; LUMINESCENCE; METABOLIC DISORDER; NEOPLASM; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SCIENTIST;

EID: 45949106612     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.6.607     Document Type: Review

References (53)

1. Manning G, Whyte DB, Martinez R, et al. Protein kinase complement of the human genome. Sciences 2002;298:1912-34
2. Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Disc. 2002;9:727-30
3. Cohen P. Protein kinases: the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-15
4. Vieth M, Sutherland JJ, Robertson DH, Campbell RM. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today 2005;10:839-46
5. Fox S, editor. High-throughput screening. new strategies and technologies. Moraga, CA: High-Tech Business Decisions; 2002
6. Hemmila IA, Hurskainen P. Novel detection stranoes for drug discovery. Drug Discov Today 2002;7:150-6
7. Olive DM. Quantitative methods for the analysis of protein phosphorylation in drug development. Expert Rev Proteomics 2004;1:327-41
8. Comely J. Kinase screening and profiling - spoilt for choice. Available from: http://www.ddw-online.com/data/pdfs/2006kinase%20screening.pdf
9. Sills MA, Weiss D, Pham Q, et al. Comparison of assays technologies for a tyrosine kinase assay generates different results in high throughput screening. J Biomol Screen 2002;7:191-9
10. Wu X, Glickman JF, Bowen BR, Sills MA. Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists. J Biomol Screen 2003;8:381-92
11. Beasley JR, McCoy PM, Watker TL, Dunn DA. Miniaturization, ultra-high throughput screening of tyrosine kinase using homogeneous, competitive fluorescence immunoassays. Assay Drug Dev Technol 2004;2:141-52
12. Zhang JH, Wu X, Sills MA. Probing the primary screening efficiency by multiple replicate testing: a quantitative analysis of hit confirmation and false screening results of a biochemical assay. J Biomol Screen 2005;10:695-704
13. Wu X, Sills MA, Zhang JH. Further comparison of primary hit identification by different assay technologies and effects of assay measurement variability. J Biomol Screen 2005;9:581-9
14. Ahsen OV, Schmidt A, Klotz M, Parczyk K. Assay concordance between SPA and TR-FRET in high-throughput screening. J Biomol Screen 2006;11:606-16
15. Quercia AK, Lamarr WA, Myung J, et al. High-throughput screening by mass spectrometry: comparison with the scintillation proximity assay with a focused-file screen of AKT1/PKB. J Biomol Screen 2007;12:473-80
16. Kashem MA, Nelson RM, Yingling JD, et al. Three mechanistically distinct kinase assay compared: measurement of intrinsic ATPase activity identified the most comprehensives set of ITK inhibitors. J Biomol Screen 2007;12:70-83
17. Available from: http://reactionbiology.com/pages/kinase.htm
18. Available from: http://www.millipore.com/drugdiscovery/dd2/kinasetarget
19. Available from: http://www.rcxg.mdlc.com/aptrix./upp01077.nsf/Content/ Products?OpenDocument&parentid=658513&moduleid=166937
20. Available from: http://las.perkinelmer.com/Catalog/ default.htm?CategoryID=Scintillation+Proximity+Assay+%5BSPA%5D
21. Available from: http://www.proqinase.com/pages/service/p2_1_4.html
22. Charter NW, Kauffman L, Singh R, Eglen RM. A generic, homogenous method for measuring kinase and inhibitor activity via adenosine 5′-diphosphate accumulation. J Biomol Screen 2006;11(4):390-9 [Epub 28 Apr 2006]
23. Available from: http://www.promega.com/paguide/chap7.pdf
24. Ma H, Horiuchi KY, Wang Y, et al. Nanoliter homogeneous ultra-high throughput screening microarray for lead discoveries and IC50 profiling. Assay Drug Dev Technol 2005;3;177-87
25. Engelman JA, Luo J, Candey LC. The evolution of Phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev 2006;7:606-19
26. Available from: http://www.invitrogen.com/downloads/ Redder_formated_poster.pdf
27. Available from: http://www.invitrogen.com/ content.cfm?pageid=10413#selection
28. Available from: http://www.invitrogen.com/content.cfm?pageid=9866
29. Horiuchi KY, Wang Y, Diamond SL, Ma H. Microarrays for the functional analysis of the chemical kinase interactome. J Biomol Screen 2006;11:48-56
30. Ma H, Horiuchi KY. Chemical microarray: a new tool for drug screening and discovery. Drug Discov Today 2006;11:661-8
31. Available from: http://www.carnabio.com/english/product/assay.html
32. Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 2007;5:127-36
33. Available from: http://www.nanostream.com/support/downloads.html
34. Dunne J, Reardon H, Trinh V, et al. Comparison of on-chip and off-chip microfluidic kinase assay formats. Assay Drug Dev Technol 2004;2:121-9
35. Available from: http://www.ambitbio.com/technology/
36. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36
37. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitors selectivity. Nat Biotechnol 2007;26:127-32
38. Vainshtein I, Silveria S, Kaul P, et al. A high-throughput, nonisotopic, competitive binding assay For kinases using nonselective inhibitor probes (ED-NSIP™). J Biomol Screen 2002;6:497-504
39. Horiuchi KY, Ma H. Fluorescence polarization and time-resolved fluorescence resonance energy transfer techniques for PI3K assays. In: Ana Cecilia Roque, editor, Ligand-macromolecule interactions in drug discovery. The Humana Press, Inc.; 2008
40. Hubert CL, Sherling SE, Johnston PA, Stancato LF. Data concordance from a comparison between filter binding and fluorescence polarization assay formats for identification of ROCK-II inhibitors. J Biomol Screen 2003;8:399-409
41. Buolamwini JK, Kamath S. Molecular-kinase interaction map, Opinion and comment section. Nat Biotechnol 2005;11:1346-8
42. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
43. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6
44. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005;23:2946-54
45. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(14S Suppl):7022
46. Ratain MJ, Flaherty KT, Stadler WM, et al. "Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). ASCO Proceedings". J Clin Oncol 2004;23:A4501
47. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
48. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
49. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias N Engl J Med 2006;354:2531-41
50. Shah N, Sawyers CL, Kantarjian HM, et al. Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL). 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S Suppl Pt I of II):565s [Abstract 6521]
51. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
52. Fazio N, Dettori M, Lorizzo K, et al. Temsirolimus for advanced renal-cell carcinoma. N Engl J Med 2007;357:1050-10
53. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive AL. N Engl J Med 354:2542-51